echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The latest data from the Phase II clinical trial of Sagimet's partner, Sagimet, shows that ASC40 (TVB-2640) has a positive effect on NASH patients in China and the United States

    The latest data from the Phase II clinical trial of Sagimet's partner, Sagimet, shows that ASC40 (TVB-2640) has a positive effect on NASH patients in China and the United States

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hangzhou and Shaoxing, China, November 12, 2021/PRNewswire/ - Golly Pharmaceutical Co.


    As the primary coordinating investigator of the study, Dr.


    About Sagimet

    Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment of important diseases, such as non-alcoholic steatohepatitis (NASH) and certain cancers, focusing on dysfunctional metabolic pathways


    About songli

    Gale is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.


    1.


    2.


    3.


    4.


    Source: Golly Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.